Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-HAE Phase 3 study of ADX-324 in hereditary angioedema
2025-521352-38-00Phase 3Authorised
- Sponsor
- ADARx Pharmaceuticals
- Start
- Jan 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in hereditary angioedema (HAE) comparing ADX-324 with Placebo (2 arms). Planned start Jan 2026; status: authorised.
02
Drugs
onvuzosiran
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2025-521352-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521352-38-00.